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1350Available online 5 July 2020Background: Patients with brain metastases (BM) from human epidermal growth factor receptor 2 (HER2)-positive
breast cancer represent a difficult-to-treat population. Trastuzumab emtansine (T-DM1) has shown potential activity
in this subset of patients in small clinical series.
Patients and methods: KAMILLA is an ongoing, phase IIIb study of T-DM1 in patients with HER2-positive locally
advanced/metastatic breast cancer with prior HER2-targeted therapy and chemotherapy. Patients received T-DM1
3.6 mg/kg every 3 weeks (intravenously) until unacceptable toxicity, withdrawal of consent, or disease progression.
Tumor response and clinical outcomes in patients with baseline BM were evaluated in this post hoc, exploratory
analysis. The main outcome measures were best overall response rate (complete response þ partial response) and
clinical benefit rate (complete response þ partial response þ stable disease lasting 6 months) by RECIST v1.1
criteria, progression-free survival, overall survival, and safety.
Results: Of 2002 treated patients, 398 had baseline BM. In 126 patients with measurable BM, the best overall response
rate and clinical benefit rate were 21.4% [95% confidence interval (CI) 14.6e29.6] and 42.9% (95% CI 34.1e52.0),
respectively. A reduction in the sum of the major diameters of BM 30% occurred in 42.9% (95% CI 34.1e52.0),
including 49.3% (95% CI 36.9e61.8) of 67 patients without prior radiotherapy to BM. In the 398 patients with
baseline BM, median progression-free survival and overall survival were 5.5 (95% CI 5.3e5.6) months and 18.9 (95%
CI 17.1e21.3) months, respectively. The adverse event profile was broadly similar in patients with and without
baseline BM, although nervous system adverse events were more common in patients with [208 (52.3%)] versus
without [701 (43.7%)] baseline BM.
Conclusion: This exploratory analysis of patients with HER2-positive metastatic breast cancer and BM enrolled in a
prospective clinical trial shows that T-DM1 is active and well-tolerated in this population. T-DM1 should be explored
further in this setting.
Trial registration: ClinicalTrials.gov identifier: NCT01702571.
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Patients with human epidermal growth factor receptor 2
(HER2)-positive breast cancer are at high risk for developing
metastatic disease in the central nervous system (CNS),
particularly of the brain.1e3 Brain metastases (BM) are
associated with poor outcomes,4,5 and treatment options
for patients with HER2-positive metastatic breast cancer
(MBC) and BM are limited.6 Accumulating evidenceVolume 31 - Issue 10 - 2020
F. Montemurro et al. Annals of Oncologyindicates that systemic treatment that includes HER2-
targeted agents may improve clinical outcomes in patients
with HER2-positive MBC and BM; survival in such patients
has been reported as approximately 11e30 months.7e12
Studies of the epidermal growth factor receptor/HER2-
targeted tyrosine kinase inhibitors (TKIs) lapatinib and
neratinib (alone or in combination with capecitabine), and
the HER2-specific TKI tucatinib (in combination with
trastuzumab and capecitabine), have reported activity in
patients with HER2-positive MBC and BM.7,10,13e17 Among
other potentially active drugs in these patients, the
antibody-drug conjugate trastuzumab emtansine (T-DM1)
has been shown to improve overall survival (OS) in patients
with trastuzumab-resistant advanced MBC and asymptom-
atic BM previously treated with radiotherapy, compared
with lapatinib plus capecitabine.11 Two small additional
studies also provided signals of clinical activity for T-DM1 in
patients with HER2-positive MBC and BM.18,19
KAMILLA (NCT01702571) is an ongoing, international,
single-arm, open-label, phase IIIb study evaluating the
safety and efficacy of T-DM1 in patients with previously
treated, HER2-positive advanced breast cancer. The primary
analysis found that T-DM1 was well tolerated and showed
efficacy consistent with that reported in previous studies.20
Here, we report the results of a post hoc exploratory
analysis describing T-DM1 safety and efficacy in patients
with and without baseline BM based on final cohort 1 data
from KAMILLA.MATERIALS AND METHODS
Overall KAMILLA study: patients and study design
The design of the ongoing, two-cohort KAMILLA study has
been reported previously.20 Cohort 1 had a target enrollment
of 2000 patients; primary results have been reported.20 To
date, 182 patients have been enrolled in cohort 2, which in-
cludes only patients fromAsian countries; follow-up is ongoing.
Eligible patients had received prior HER2-targeted ther-
apy and chemotherapy, and had progressed on or after
their most recent treatment of advanced breast cancer, or
within 6 months of completing adjuvant therapy.20 Patients
with untreated, asymptomatic BM or controlled brain dis-
ease treated with radiotherapy >14 days before enrollment
were eligible. Patients provided written informed consent.
The study was approved by the institutional review board at
each site and was conducted in accordance with the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Hu-
man UsedeGood Clinical Practice: Consolidated Guideline.
Participating patients received T-DM1 3.6 mg/kg every
3 weeks (intravenously) until unacceptable toxicity,
withdrawal of consent, or disease progression.20Exploratory analysis of patients with BM: outcomes and
statistical methods
The objective of this post hoc exploratory analysis of
patients in cohort 1 was to evaluate T-DM1 clinical activityVolume 31 - Issue 10 - 2020and safety in the subgroup of patients with BM at baseline.
To minimize the bias of late responses in target CNS lesions
following radiotherapy in patients with measurable baseline
BM, T-DM1 clinical activity was also evaluated in subgroups
defined by prior brain radiotherapy: <30 days before
baseline, 30 days before baseline, or no radiotherapy.
Information is also provided for patients who continued
treatment with T-DM1 after disease progression.
Tumor assessments were made in accordance with
RECIST version 1.1 at screening and every 12 weeks there-
after,21 based on both target and non-target lesions in the
body and brain. Tumor response definitions are provided in
supplementary Methods, available at Annals of Oncology
online. The Clopper-Pearson method was used to estimate
the exact two-sided 95% confidence interval (CI) for
proportions.
Follow-up for survival occurred every 6 months (14
days) until death, loss to follow-up, or withdrawal of con-
sent. Median progression-free survival (PFS) and OS were
estimated using the KaplaneMeier method. Definitions for
PFS and OS are provided in supplementary Methods,
available at Annals of Oncology online. The Brookmeyer-
Crowley method was used to construct the two-sided
95% CI for median PFS and OS. Adverse events (AEs) were
assessed throughout the study.
A univariate Cox proportional hazards model was used to
explore the prognostic effect of brain involvement (yes
versus no) at baseline on OS. In addition, an exploratory
multivariable Cox proportional hazards model was
employed to assess the association of other potential
prognostic factors with OS and to adjust the BM effect for
these factors. Estimates of hazard ratio (HR), with corre-
sponding 95% two-sided CI and P value (based on the Wald
test), were provided for covariates retained in the final Cox
model. Further details on the multivariable Cox model are
reported in supplementary Methods, available at Annals of
Oncology online. Due to the exploratory nature of the
analyses, no multiplicity adjustments were carried out.
RESULTS
Patients
In total, 2003 patients were enrolled in study cohort 1
between 12 November 2012, and 29 September 2014,
and 2002 patients received treatment with T-DM1
(supplementary Figure S1A, available at Annals of Oncology
online). At database lock (31 January 2017), median follow-
up duration was 20.6 months (range 0e50).20 Of the
treated patients, 398 had baseline BM reported in the
database (supplementary Figure S1B, available at Annals of
Oncology online). Demographics and disease characteristics
for the subgroups of patients with and without baseline BM
were generally comparable (Table 1). However, numerically
fewer patients with baseline BM had an Eastern Coopera-
tive Oncology Group (ECOG) performance status of 0. Of the
398 patients with baseline BM, 126 (31.7%) had measurable
BM designated as target lesions for the evaluation of
treatment response. In this subset, 7.9% (10/126), 38.9%https://doi.org/10.1016/j.annonc.2020.06.020 1351
Table 1. Demographics and disease characteristics at baseline
BM at baseline
(n [ 398)
No BM at baseline
(n [ 1604)
Median age, years (range) 52 (28e83) 55 (26e88)
ECOG performance status, n (%)
0 192 (48.2) 918 (57.2)
1 174 (43.7) 601 (37.5)
2 32 (8.0) 83 (5.2)
Hormone receptor status of the
primary tumor, n (%)
ER- and/or PR-positive 246 (61.8) 986 (61.5)
ER- and/or PR-negative 150 (37.7) 603 (37.6)
Both unknown/not done 2 (0.5) 15 (0.9)
Stage IV disease at initial
diagnosis,a n (%)
122 (30.7) 425 (26.5)
Median time since initial breast
cancer diagnosis, years (range)
4.8 (0e28) 5.0 (0e53)
Median time since first metastasis,
years (range)
2.4 (0e25) 2.6 (0e35)
Prior lines of treatment of metastatic
disease, n (%)
None 9 (2.3) 18 (1.1)
1L 93 (23.4) 474 (29.6)
2L 91 (22.9) 355 (22.1)
3L 75 (18.8) 283 (17.6)
4L 49 (12.3) 152 (9.5)
5L 74 (18.6) 242 (15.1)
Missing 7 (1.8) 80 (5.0)
Type of previous systemic cancer
therapy (any setting),b n (%)
Chemotherapy 395 (99.2) 1603 (99.9)
Targeted therapy 398 (100.0) 1603 (99.9)
Endocrine therapy 227 (57.0) 946 (59.0)
Radiotherapy 351 (88.2) 1235 (77.0)
Previous anticancer therapy
(any setting),b n (%)
Anthracyclines 280 (70.4) 1143 (71.3)
Taxanes 373 (93.7) 1473 (91.8)
Lapatinib 237 (59.5) 711 (44.3)
Trastuzumab 392 (98.5) 1584 (98.8)
Pertuzumab 24 (6.0) 65 (4.1)
Endocrine therapy 225 (56.5) 932 (58.1)
Prior brain radiotherapy
(any setting), n (%)
226 (56.8) NAc
1L, first-line; 2L, second-line; 3L, third-line; 4L, fourth-line; 5L, fifth-line; BM, brain
metastases; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; NA,
not applicable; PR, progesterone receptor.
a An additional 11 patients with baseline BM and 46 patients without baseline BM
had unmeasurable metastases or unknown stage at breast cancer diagnosis.
b Patients could have received more than one type of prior therapy.
c Ninety-one patients had accounts of radiotherapy to the brain before study entry,
but no documented BM lesions at baseline. Since no further information was
available on the existence of BM lesions at baseline for these patients, they were
included in the group of patients without BM at baseline.
Annals of Oncology F. Montemurro et al.(49/126), and 53.2% (67/126) had received brain radio-
therapy <30 days before baseline, 30 days before base-
line [median 8.4 months (interquartile range 5.0e13.8;
range 1.0e45.3)], or had not received brain radiotherapy,
respectively.Treatment exposure
Median duration of T-DM1 exposure was 4.9 months (range
0e44) in patients with baseline BM and 5.8 months (range
0e46) in those without.1352 https://doi.org/10.1016/j.annonc.2020.06.020Overall tumor response in patients with RECIST Version 1.1
measurable BM at baseline
Of the 126 patients with measurable BM at baseline, 3
achieved a complete response and 24 achieved a partial
response, corresponding to a best overall response (BOR)
rate across all organs of 21.4% (27/126; 95% CI 14.6e29.6)
(Figure 1A and B). An additional 27 patients experienced
stable disease (SD) lasting 6 months, resulting in a clinical
benefit rate of 42.9% (54/126; 95% CI 34.1e52.0)
(supplementary Figure S2, available at Annals of Oncology
online). A 30% reduction in the sum of the largest
diameters of target brain lesions was observed in 42.9%
(54/126; 95% CI 34.1e52.0) of patients, including those
whose overall disease response was SD or progressive
disease (PD) per RECIST version 1.1.
In the 126 patients with measurable BM, a 30%
reduction in the sum of the largest diameters of target brain
lesions was observed in 50.0% (5/10; 95% CI 18.7e81.3),
32.7% (16/49; 95% CI 20.0e47.6), and 49.3% (33/67; 95% CI
36.9e61.8) of patients who received brain radiotherapy
<30 days before baseline, 30 days before baseline, and
did not receive brain radiotherapy, respectively (Figure 1C).
In these 54 patients with a 30% reduction in the sum of
the largest diameters of target brain lesions, including 9
patients who continued T-DM1 beyond CNS progression,
the median duration of exposure to T-DM1 was 9.5 months
(range 0.8e43.5). Target lesion evolution over time for
patients who did and did not receive radiotherapy is shown
in Figure 2.
Survival outcomes (overall population)
Median PFS was 5.5 months (95% CI 5.3e5.6) in patients
with and 7.7 months (95% CI 6.8e8.1) in those without
baseline BM (Figure 3A). In patients with BM, median PFS
did not appear to be affected by line of treatment with
T-DM1 (supplementary Figure S3, available at Annals of
Oncology online).
Median OS was 18.9 months (95% CI 17.1e21.3) in
patients with baseline BM and 30.0 months (95% CI 27.6e
31.2) in those without (Figure 3B). Potential prognostic
factors for OS were evaluated by exploratory Cox model
(supplementary Table S1, available at Annals of Oncology
online). In the univariate analysis, the presence of brain
lesions at baseline was associated with decreased OS
[estimated HR 1.68 (95% CI 1.46e1.93; P < 0.0001)]. In the
multivariable Cox analyses, brain involvement at baseline
remained a statistically significant variable. However, the
adjusted BM effect estimate had a lower magnitude [esti-
mated HR for adjusted BM effect 1.18 (95% CI 1.02e1.38;
P ¼ 0.0268)]; and several additional variables were found to
be potentially associated with decreased OS, including older
age, shorter time since diagnosis of metastatic disease,
ECOG performance status 1, presence of liver metastases,
greater number of metastatic sites, and greater lines of
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Figure 1. Treatment response in brain and non-brain target lesions in patients
with measurable brain metastases.
(A) Percent change in sum of dimensions of target brain lesions. (B) Percent
change in sum of dimensions of target non-brain lesions. (C) Percent change in
sum of dimensions of target brain lesions by radiotherapy subgroup.
Bars are ordered in accordance with decreasing percent change in the sum of
target lesion dimensions in brain metastases. Positive bars show growth in target
lesions and negative bars indicate shrinkage. Color coding specifies the overall
response per RECIST version 1.1 in panels (A) and (B), and by radiotherapy group
in panel (C). The dotted lines correspond to a 20% increase or 30% reduction in
the size of the target lesion(s).
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Volume 31 - Issue 10 - 2020Continued T-DM1 exposure in patients with new brain
lesions
A total of 269 patients experienced new brain lesions during
T-DM1 treatment. These included 28.9% (115/398) of pa-
tients with baseline BM and 9.6% (154/1604) without
baseline BM. KAMILLA allowed continuation of T-DM1 in
patients with controlled systemic disease and new brain
progression that was amenable to surgery and/or radio-
therapy. Sixty-nine patients had investigator-reported
continuation of T-DM1 treatment beyond brain progres-
sion, of whom 40 had baseline BM and 29 did not. The
baseline demographics and disease characteristics of this
subset of patients are summarized in supplementary
Table S2, available at Annals of Oncology online. Among
these patients, subsequent T-DM1 treatment administration
data (post-progression) were available for 67 patients: the
median duration of T-DM1 treatment post-progression was
6.2 months (range 0e37), with durations of 8.8 months
(range 0e37) and 6.2 months (range 1e28) in patients with
(n ¼ 39) and without (n ¼ 28) baseline BM, respectively.Safety
Any AEs and serious AEs were reported in 92.5% (368/398)
and 28.4% (113/398) of patients with and in 93.1% (1494/
1604) and 19.6% (314/1604) of patients without baseline
BM, respectively. The incidence of individual all-grade AEs
was generally similar between BM subgroups
(supplementary Table S3, available at Annals of Oncology
online); however, headache and vomiting occurred in a
slightly higher percentage of patients with baseline BM and
pyrexia occurred in a higher percentage of patients without
baseline BM. Nervous system AEs were more common in
patients with [n ¼ 208 (52.3%)] versus without [n ¼ 701
(43.7%)] baseline BM. The following individual serious AEs
had a 1.0% difference between subgroups of patients
with versus without BM, respectively: epilepsy [n¼ 6 (1.5%)
versus n ¼ 2 (0.1%)], seizure [n ¼ 6 (1.5%) versus n ¼ 1
(0.1%)], and brain edema [n ¼ 5 (1.3%) versus n ¼ 1
(0.1%)]. Grade 3 AEs occurring in 1% of all patients and
patients with versus without BM are summarized in
supplementary Table S4, available at Annals of Oncology
online. Grade 3 CNS hemorrhage occurred in four patients
with baseline BM (grade 3 intracranial hemorrhage, n ¼ 1;
grade 3 and 4 cerebral hemorrhage, each n ¼ 1; and grade
4 hemorrhagic stroke, n ¼ 1) and two patients without
baseline BM (grade 3 and grade 5 intracranial hemorrhage,
each n ¼ 1).
Grade 5 AEs were reported in 3.5% (n ¼ 14) of patients
with baseline BM and 1.9% (n ¼ 31) of patients without
baseline BM. Among patients with baseline BM, brain
edema was the only grade 5 AE reported in >1 patientTriangles in panel B indicate patients with no change available (e.g. due to having
no metastatic lesions outside of the brain). Asterisks in panel (C) indicate patients
who progressed by the first tumor assessment.
BOR, best overall response; CR, complete response; PD, progressive disease; PR,
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Figure 2. Brain target lesion evolution over time for patients with measurable brain metastases at baseline.
(A) Target lesion evolution in patients who received brain radiotherapy <30 days or 30 days before baseline. (B) Target lesion evolution in patients who did not receive
radiotherapy before baseline.
One patient with radiotherapy and three patients without radiotherapy had a percent change from baseline greater than 100%, indicated with ‘*’. One patient without
radiotherapy had a change from baseline of 120% with a last assessment at 33.2 months, outside of the plot area. The dotted lines correspond to a 20% increase or 30%
reduction in the size of the target lesion(s). Six patients with radiotherapy and seven patients without radiotherapy had target lesion assessments after 24 months,
indicated with ‘þ’.
Annals of Oncology F. Montemurro et al.(n ¼ 2). Grade 5 AEs in >1 patient without baseline BM
were renal failure (n ¼ 3) and multiple organ dysfunction,
sepsis, peritonitis, pneumonitis, and hepatic failure (each
n ¼ 2). Similar proportions of patients in each subgroup
reported AEs as the primary reason for permanent treat-
ment discontinuation [n ¼ 43 (10.8%) and n ¼ 198 (12.3%)
in patients with and without baseline BM, respectively].
Among the 69 patients who continued T-DM1 treatment
following progression in the brain, serious AEs were1354 https://doi.org/10.1016/j.annonc.2020.06.020observed in 26.1% (n ¼ 18). Seizure and confusional state
[each n ¼ 2 (2.9%)] were the only serious AEs reported in
>1 patient. Median PFS from the start of T-DM1 in this
subgroup was 10.9 months (95% CI 8.2e12.9).
DISCUSSION
KAMILLA included the largest population to date of patients
with HER2-positive advanced breast cancer and BM treated











































































BM at baseline 18.9 (17.1–21.3)












































































BM at baseline  5.5 (5.3–5.6)




Figure 3. Progression-free survival and overall survival in patients with and without brain metastases at baseline.
(A) Progression-free survival. (B) Overall survival.
BM, brain metastases; CI, confidence interval.
F. Montemurro et al. Annals of OncologyAlthough KAMILLA was not specifically designed to address
T-DM1 activity in this particular patient population, our post
hoc analysis provides some interesting insights. First, in
patients with measurable BM (n ¼ 126), the BOR and
clinical benefit rate were 21.4% and 42.9%, respectively.Volume 31 - Issue 10 - 2020These figures can be considered clinically relevant in this
heavily pretreated population. Second, 42.9% of these pa-
tients achieved a 30% reduction in the sum of major
diameter of RECIST-evaluated BM, including patients with
PD as the BOR. In this latter group of patients, eight alsohttps://doi.org/10.1016/j.annonc.2020.06.020 1355
Annals of Oncology F. Montemurro et al.showed a concomitant reduction in non-CNS target lesions
(Figure 1B). Therefore, PD as BOR could have been due to
the progression of non-target lesions (across all organs), the
appearance of new lesions (across all organs), or significant
clinical deterioration. Unfortunately, the data collected in
KAMILLA do not provide the granularity needed to assess
the pattern of disease progression in each patient. In the 67
patients without radiotherapy to target BM before study
entry, 49.3% had a 30% reduction in the sum of the major
diameters of BM. As this is unbiased by prior radiotherapy
or other forms of local therapy to the brain, it represents
the direct therapeutic effect of T-DM1 in BM. Because
reduction in the size of BM is associated with improvements
in neurological symptoms, it is possible (although not
formally assessed) that patients with a BM response expe-
rienced clinically meaningful benefits on neurological end
points; this interesting point warrants further research.
Third, compared with patients without BM at study entry,
patients with BM experienced reduced PFS and OS,
underscoring the importance of continued research in this
field. Fourth, patients with new brain lesions during
treatment with T-DM1 may still benefit from continuation
of T-DM1 after local treatment of BMs. When interpreting
the encouraging PFS outcomes in this subset of patients,
one must consider that these patients were selected for
having SD or better outside of the CNS and progressing BMs
that could have been managed with local treatmentda
course of action aligned with current guidelines.22 To our
knowledge, this is the first descriptive report of outcomes in
clinical trial participants who continued T-DM1 beyond
isolated CNS progression. Finally, the overall safety profile
for T-DM1 was generally similar between patients with and
without baseline BM, although as expected, numerically
more nervous system AEs were reported for the former.
Overall, this analysis points to the potential of T-DM1
for the treatment of patients with HER2-positive MBC and
BM.
Initial reports suggested that trastuzumab had little or no
activity in the CNS due to difficulty penetrating the blood-
brain barrier.23 Therefore, much of the research in pa-
tients with HER2-positive MBC and BM has focused on small
molecule TKIs, namely lapatinib, neratinib, and tucati-
nib.7,10,13e17 Our reported median PFS, based on a large
number of patients and events, is within the range of those
described with lapatinib or neratinib plus capecitabine in
patients with BM,7,13 while the three-drug combination of
tucatinib, trastuzumab, and capecitabine yielded superior
median PFS in the HER2CLIMB trial.17 In this trial, 75 pa-
tients had untreated, RECIST-measurable CNS metastases at
baseline, and patients treated with the three-drug combi-
nation achieved an intracranial ORR of 47.3%.24 Obviously,
cross-trial comparisons should be taken with caution and
may serve, at best, for hypothesis generation. Yet, anti-
tumor activity for T-DM1 in BM from HER2-positive breast
cancer is plausible and has supporting preclinical data.
Despite similar drug tissue distribution, T-DM1, but not
trastuzumab, significantly delayed the growth of metastases1356 https://doi.org/10.1016/j.annonc.2020.06.020by inducing apoptosis and mitotic catastrophe in mouse
models of HER2-positive MBC with BM.25
As they are post hoc and exploratory, the analyses re-
ported here should be interpreted with caution and
considered hypotheses-generating. KAMILLA used RECIST
v1.1 to describe tumor response across all organs (CNS and
non-CNS). As the recruitment of clinical trial participants
with CNS metastases is becoming a research priority, limi-
tations of RECIST v1.1 in correctly describing the CNS ac-
tivity of systemic therapy have become evident.26 The more
recently proposed Responses Assessment Criteria for Brain
Metastases (RANO-BM) criteria provide the means for
evaluating treatment responses in patients with CNS
metastases.27 These include bicompartmental evaluation of
PFS (CNS and non-CNS assessed separately and then
combined for different definitions of PFS) and, more
importantly, neurological deterioration and the correlative
use of palliative steroid treatment.
Small patient numbers are another limitation to the
interpretation of some analyses. For example, analyses of
patients with radiotherapy <30 days before baseline and of
patients who continued treatment after progression in the
brain were based on small cohorts. Another potential lim-
itation to the generalizability of our results is that only a
small proportion (4.4%) of patients in KAMILLA had been
exposed to pertuzumab before study entry. Pertuzumab
plus trastuzumab and chemotherapy is the recommended
first-line treatment of patients newly diagnosed with HER2-
positive advanced breast cancer.28 While controversy exists
regarding the potential for reduced efficacy of T-DM1 in
patients previously exposed to pertuzumab,29e32 it is rele-
vant to acknowledge that most patients in KAMILLA did not
receive the current standard-of-care for first-line treatment
of MBC.
Despite advances in the treatment of HER2-positive MBC,
a notable unmet need remains for patients who also have
BM. This exploratory subgroup analysis of KAMILLA
represents the largest reported cohort of patients with
HER2-positive MBC and BM treated with T-DM1 in a
prospective setting. We observed clinically meaningful
antitumor activity in patients with and without prior
radiotherapy, suggesting that T-DM1 is active in this popu-
lation and warrants further exploration.ACKNOWLEDGEMENTS
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